• Intra-cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders.
• Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at three upcoming investor conferences.
• The Morgan Stanley 22nd Annual Global Healthcare Conference will be held on September 4, 2024, in New York.
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Wednesday, September 4, 2024 at 10:00 a.m. ET in New York, NY
Baird’s 2024 Global Healthcare Conference
Wednesday, September 11, 2024 at 11:25 a.m. ET in New York, NY
2024 Cantor Global Healthcare Conference
Wednesday, September 18, 2024 at 10:55 a.m. ET in New York, NY
A live and achieved webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Cameron Radinovic
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-930-4406
| Last Trade: | US$75.28 |
| Daily Change: | -0.10 -0.13 |
| Daily Volume: | 267,280 |
| Market Cap: | US$7.950B |
August 08, 2024 August 07, 2024 June 10, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
